Authors: Thomas Reiss, Iciar Dominguez Lacasa
Addresses: Department Emerging Technologies, Fraunhofer Institut for Systems and Innovation Research (ISI), Breslauer Str. 48, 76139 Karlsruhe, Germany. ' Chair for Innovation Management and Small Business Research, International Graduate School Zittau, Markt 23, 02763 Zittau, Germany
Abstract: This paper presents an analysis of the performance of the European Union (EU) member states and the USA in biotechnology based on various science, technology and commercialisation indicators. The performance analysis shows that European countries can be grouped into three clusters: Cluster 1, with the best-performing countries, includes Switzerland, Denmark, Sweden and Finland. Cluster 2 performs at a level that is roughly similar to the European median and includes Austria, Belgium, the Netherlands, Ireland, Norway, Germany, France and the UK. Cluster 3 – Italy, Greece, Spain, Portugal and Luxembourg – performs well below the European median. The best-performing European countries achieve higher performance scores than the USA. Within the whole spectrum of the considered European countries, the USA would be positioned in the first half. The comparison of the scientific and commercialisation performance of the individual countries reveals clear evidence for a positive correlation between scientific and commercial performance.
Keywords: biotechnology; performance measurement; indicators; Europe; USA; United States; EU; European Union; science; commercialisation.
International Journal of Biotechnology, 2008 Vol.10 No.4, pp.303 - 326
Available online: 16 Jul 2008 *Full-text access for editors Access for subscribers Purchase this article Comment on this article